Pembrolizumab

Pembrolizumab Reactions 1704, p301 - 2 Jun 2018 Haemoptysis: case report A 64-year-old man died of massive haemoptysis during treatment with pembrolizumab for stage-IVb lung adenocarcinoma [route not stated]. The man was scheduled to receive treatment with pembrolizumab 200mg every 21 days. rd On 3 November, the first dose of pembrolizumab was administered without any immediate side effects. His social history was significant for smoking and had no previous episodes of haemoptysis. On day 15, he developed massive haemoptysis and died. Author comment: "As the tumor was NSCLC strongly positive PD-L1, firstline pembrolizumab, a 200-mg flat dose every 21 days, was scheduled . . . The achievement of a great response and shrinkage in centrally located lung tumors with vascular involvement may be not so uncommon in strongly PDL1–positive NSCLC when pembrolizumab is used in the first-line setting. Therefore, the risk for severe bleeding may be a real concern." Artal-Cortes A, et al. Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC. Journal of Thoracic Oncology 13: e76-e77, No. 5, May 2018. Available from: URL: http:// doi.org/10.1016/j.jtho.2017.12.004 - Spain 803323731 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Pembrolizumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/pembrolizumab-2ZTnP6Xg6G
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46944-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p301 - 2 Jun 2018 Haemoptysis: case report A 64-year-old man died of massive haemoptysis during treatment with pembrolizumab for stage-IVb lung adenocarcinoma [route not stated]. The man was scheduled to receive treatment with pembrolizumab 200mg every 21 days. rd On 3 November, the first dose of pembrolizumab was administered without any immediate side effects. His social history was significant for smoking and had no previous episodes of haemoptysis. On day 15, he developed massive haemoptysis and died. Author comment: "As the tumor was NSCLC strongly positive PD-L1, firstline pembrolizumab, a 200-mg flat dose every 21 days, was scheduled . . . The achievement of a great response and shrinkage in centrally located lung tumors with vascular involvement may be not so uncommon in strongly PDL1–positive NSCLC when pembrolizumab is used in the first-line setting. Therefore, the risk for severe bleeding may be a real concern." Artal-Cortes A, et al. Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC. Journal of Thoracic Oncology 13: e76-e77, No. 5, May 2018. Available from: URL: http:// doi.org/10.1016/j.jtho.2017.12.004 - Spain 803323731 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off